Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 16/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983780 | 0.85 | ADRB2 (0.55) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL12226017 | 0.85 | ADRB2 (0.48) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL2179812 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL2179807 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL2179816 | 0.84 | ADRB2 (0.69) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL6917173 | 0.84 | MAPT (0.53) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL27814469 | 0.83 | ADRB2 (0.49) | ADRB2ADRB1ADRB3 | |
| SCHEMBL9579629 | 0.83 | ELANE (0.54) | ADRB2ADRB1ADRB3ELANEHSD17B10 | |
| SCHEMBL207184 | 0.81 | ADRB2 (0.68) | ADRB2ADRB1ADRB3MAPT | |
| SCHEMBL13809633 | 0.80 | PTPN1 (0.56) | ADRB2ADRB1ADRB3ELANEHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968684-B2 | Polymer-NSAID conjugate | POLYACTIVA PTY LTD (AU) | 2018-05-15 | — | — | US | disclosed |
| US-20150150999-A1 | POLYMER-NSAID CONJUGATE | POLYACTIVA PTY LTD (AU) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150999-A1 | POLYMER-NSAID CONJUGATE | PTGS1, PTGES3, PTGES | ADRB2 4120/4885ADRB1 3131/4885ADRB3 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.